Jain et al demonstrated that CRISPR‐Cas9‐based treatment of myocilin‐associated glaucoma using myocilin mouse model of POAG.83 The problem for this model is that the authors use CRISPR‐Cas9‐based genome editing, which may result in unwanted genetic consequences. Here, MYOC is linked to glaucoma.